Calidi Biotherapeutics Closes a Notable Stock Offering
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has successfully completed a significant public offering that raised approximately $7.5 million. This closing marks a pivotal moment for Calidi, a company striving to revolutionize cancer treatment through innovative therapies. The offering consisted of 4,437,869 shares of common stock, priced at $1.69 each, showcasing strong investor interest in the company’s mission.
Role of Placement Agents in the Offering
In this offering, Ladenburg Thalmann & Co. Inc. played a crucial role as the exclusive placement agent. With their expertise, they have helped facilitate this financing, which is vital for Calidi as they continue to develop their unique therapies. Investors recognize the potential of Calidi's targeted approaches to tackling cancer and are eager to support their efforts in this challenging field.
Details of the Registration and Prospectus
Public Offering Insights
The shares in this public offering were made available under registration statements filed with the United States Securities and Exchange Commission, specifically Form S-3 (File No. 333-282456), which received approval earlier this year. Transactions like these are vital for biotech firms as they seek to secure funding for their ongoing and future clinical trials.
Availability of the Final Prospectus
While specific details regarding the offering are outlined in the final prospectus filed with the SEC, it’s important for potential investors to access this comprehensive document. This will provide further clarity on the terms of the offering and the potential risks associated with investing in early-stage biotechnology companies.
About Calidi Biotherapeutics
Calidi Biotherapeutics is an innovative biotechnology firm that is currently in the clinical stage of developing targeted immuno-oncology therapies. The company's approach centers around stimulating the immune system to combat cancer effectively. Utilizing stem cell technology, Calidi is pioneering methods that harness the power of allogeneic stem cells to deliver oncolytic viruses, which can attack tumors directly while also enhancing the immune response.
Technological Innovations at Calidi
Calidi’s proprietary approaches are particularly notable for their ability to safely and effectively amplify oncolytic viruses. These technologies aim to protect and potentiate these therapeutic agents, thereby enhancing their effectiveness against severe forms of cancer, including high-grade gliomas and various solid tumors. This dual mechanism of action positions Calidi Biotherapeutics as a frontrunner in the fight against metastatic disease.
Future Prospects and Commitment
As a company headquartered in San Diego, Calidi remains dedicated to pioneering new ways to improve the safety and efficacy of cancer treatments. The successful completion of this funding initiative not only showcases investor confidence but also bolsters the company's financial foundation to advance its clinical programs.
Frequently Asked Questions
What was the significance of Calidi Biotherapeutics' recent stock offering?
The offering raised approximately $7.5 million, allowing Calidi to advance its clinical-stage therapies and support ongoing research and trials.
Who acted as the placement agent for the offering?
Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for Calidi Biotherapeutics during this public offering.
What type of therapies does Calidi Biotherapeutics focus on?
Calidi focuses on developing targeted immuno-oncology therapies, particularly utilizing oncolytic viruses and stem cell technology to treat various forms of cancer.
How can investors access the final prospectus related to the offering?
Investors can access the final prospectus filed with the SEC through their official website or by contacting the placement agent for more information.
Where is Calidi Biotherapeutics headquartered?
Calidi Biotherapeutics is based in San Diego, California, where it focuses on innovative cancer therapies and research.
